Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -9.7% | -47.4% | 52.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 83% | 78.5% | 57.3% | 58.7% |
| R&D Expenses | $0 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $1 | $1 |
| SG&A Expenses | $0 | $0 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $2 | $2 |
| Operating Income | -$1 | -$1 | -$2 | -$2 |
| % Margin | -246.5% | -343.8% | -462.4% | -582.6% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$2 | -$2 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$1 | -$1 | -$2 | -$2 |
| % Margin | -240.9% | -355.1% | -440.6% | -583.1% |
| EPS | -10.54 | -18.37 | -50.15 | -53.83 |
| % Growth | 42.6% | 63.4% | 6.8% | – |
| EPS Diluted | -10.54 | -18.4 | -50.2 | -55.53 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$2 | -$2 |
| % Margin | -213.3% | -326.6% | -431.2% | -575.7% |